Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib + Irinotecan in Mutated Metastatic Colorectal Cancer
NCT02906059Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in metastatic colorectal cancer (mCRC), sponsored by NYU Langone Health. Primary endpoint: Dose Limiting Toxicities at 12 months. Started Sep 2016; status: completed.
02
Drugs
adavosertib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02906059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906059.